Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;54(4):337-43.
doi: 10.4103/0019-5545.104820.

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study

Suyog Mehta  1 , K Chandersekhar, G Prasadrao, Lakshman Dutt, S Patkar, R D Nagpal, M Gupta, G S P Raju, K K Praveen, B S V Prasad, T Roy, S Kushwaha, Jyotindra Nag, D Langade, D Pawar
Affiliations

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study

Suyog Mehta et al. Indian J Psychiatry. 2012 Oct.

Abstract

Background: Alzheimer's disease (AD), a progressive brain disorder, is the most common cause of dementia among the elderly. Donepezil hydrochloride is a potent, reversible, and highly selective inhibitor of acetylcholinesterase (AChE). It is chemically distinct from other cholinesterase (ChE) inhibitors which are effective in the treatment of AD.

Objectives: To evaluate the safety and efficacy of donepezil hydrochloride therapy over a 12 weeks period in patients with mild to moderate AD in Indian population.

Materials and methods: In this post-marketing study, patients with mild to moderate AD received oral donepezil hydrochloride 5 mg/day for 4 weeks followed by 10 mg/day for 8 weeks. Patients were assessed 4 times weekly for cognition on 'Mini Mental Status Examination (MMSE) scale', and function on 'Activities of Daily Living (ADL) index'. Clinicians and caregivers assessment of safety and efficacy was assessed on a 5-point rating scale.

Results: One hundred and seventy two of one hundred and eighty two patients completed 12 weeks of study period. MMSE score significantly improved (P<0.0001) from 16.72 at baseline to 19.77 after 12 weeks, and there was significant improvement (P<0.05) in ADL index in 13 of 17 domains after 12 weeks. Caregivers and clinicians rated the therapy as very good to good in >80% and >90% patients, respectively. Adverse events were consistent with the known pharmacological and safety profile of donepezil.

Conclusions: Donepezil is well tolerated in Indian patients with mild to moderate AD with significant improvement in cognition and function.

Keywords: Alzheimer's; cognition; dementia; donepezil.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Improvement in MMSE subsets (% pts.)
Figure 2
Figure 2
Global efficacy assessment by clinician and caregiver (% of pts.)
Figure 3
Figure 3
Global tolerability assessement by clinician and caregiver (% of pts.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Medez MF, Cummings JL. Dementia Significance, Definition and Epidemiology. 3rd ed. Philadelphia: Elseveir; 2006. Dementia: A Clinical Approach; pp. 1–12.
    1. Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: Characteristics and treatment. Neurol Clin. 2000;18:829–46. - PubMed
    1. Buckwalter K, Hall G. Alzheimer's disease. In: McBride AB, Austin JK, editors. Psychiatric Mental Health Nursing. Philadelphia Pa: WB Saunders Co; 1996. pp. 348–2.
    1. Cardozo MG, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. ‘QSAR anaylsis of the substituted indandone and benzylpiperidine rings of a series of indandone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem. 1992;35:584–9. - PubMed
    1. Cardozo MG, Kawai T, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. Conformational analysis and molecular shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem. 1992;35:590–601. - PubMed